Tempest Therapeutics
NASDAQ: TPSTBrisbane, US · Delaware corporation · 1 known investors
Biotech
Founders & leadership
SB
Stephen BradyDirector
CP
Christine PellizzariDirector
MA
Matthew AngelExecutive Officer, Director
RS
Ronit SimantovDirector
MR
Michael RaabDirector
NM
Nicholas MaestasExecutive Officer
TW
Thomas WoiwodeDirector
GN
Geoffrey NicholDirector
TW
Thomas W. DubenskyExecutive Officer, Director
Investors · 1
Reported raises · per SEC filings
Form D private placements▶$4.1MraisedJun 2026 · 1 investors · BiotechnologyRule 506(b)
▶$4.1MraisedJun 2026 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John David YeeDirector
- Matthew AngelExecutive Officer, Director
- Justin TrojanowskiExecutive Officer
- William Drake RicheyDirector
- Offering amount
- $4.1M
- Amount sold
- $4.1M
- First sale
- May 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedApr 2026 · 3 investors · BiotechnologyRule 506(b)
▶$2MraisedApr 2026 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stephen BradyDirector
- Christine PellizzariDirector
- Matthew AngelExecutive Officer, Director
- Ronit SimantovDirector
- Michael RaabDirector
- Nicholas MaestasExecutive Officer
- Offering amount
- $2M
- Amount sold
- $2M
- Sales commissions
- $105K
- First sale
- Mar 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15MraisedMay 2022 · 2 investors · BiotechnologyRule 506(b)
▶$15MraisedMay 2022 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stephen R. BradyExecutive Officer, Director
- Michael RaabDirector
- Ronit SimantovDirector
- Thomas WoiwodeDirector
- Geoffrey NicholDirector
- Thomas W. DubenskyExecutive Officer, Director
- Christine PellizzariDirector
- Offering amount
- $15M
- Amount sold
- $15M
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
- Tempest Therapeutics inks China in vivo CAR-T deal - TipRanks.comtipranks.com · 2026
- Tempest plans trial of in vivo CAR-T candidate for autoimmune diseases By Investing.cominvesting.com · 2026
